J&J Inks $1B Deal To Acquire Aragon Pharmaceuticals

Law360, New York (June 17, 2013, 2:03 PM EDT) -- Johnson & Johnson plans to acquire California-based Aragon Pharmaceuticals Inc. in a deal worth up to $1 billion, the companies said on Monday, in an agreement that the New Jersey pharmaceutical giant hopes will boost its efforts in prostate cancer drug development.

Under the agreement, Johnson & Johnson will pay $650 million in cash for Aragon, as well as a possible $350 million in additional payments if Aragon meets certain growth milestones, the company said in a statement. Included in the acquisition is Argon's androgen receptor...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.